---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009849"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:58:59.304009+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra restates FY2021-22 financials due to warrant errors; FY2023 revenue $27.5M

## Summary
- Q4 2023 net revenue $13.2M (vs $2.2M); FY2023 net revenue $27.5M (vs $10.2M). Net loss FY2023 $46.0M.
- Non-cash restatement: warrant liability misclassified; FY2022 net income to increase ~$14.8M; material weakness expected.
- Acer acquisition completed Nov 2023; OLPRUVA launch underway; >70% commercial/government payor coverage.
- KP1077 Phase 2 IH study met safety endpoint; clinically meaningful sleepiness improvement; Phase 3 planning.
- Arimoclomol NDA PDUFA date Sept 21, 2024; FDA plans advisory committee. Cash $67.7M; runway into 2026.

## SEC filing metadata
- accession: 0001437749-24-009849
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/0001437749-24-009849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/zvra20230627c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009849
- JSON: https://secwatch.observer/filing/0001437749-24-009849.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009849.txt

## Key facts
- Auditor Changes
  ZEVRA THERAPEUTICS, INC. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Ernst & Young LLP
  source text: and for the fiscal years ended December 31, 2022 and December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (collectively, the “Prior Financial Statements”) should no longer be relied upon. In connection with the preparation of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), the Audit Committee concluded that, in prior years it had not appropriately accounted for certain common stock warrants as liabilities. These errors led to understatements of derivative and warrant liability and additional paid-in capital and fluctuations in fair value adjustment related to derivative and warrant liability during the impacted periods. We estimate that the impacts to the periods reported in the Prior Financial Statements will result in an increase to previously reported fair valu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/0001437749-24-009849-index.htm
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $13.2M.
  - Period: fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $13.2M
  - Result: reported results
  source text: Corporate Updates Launch of OLPRUVA ® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET Celebration, FL – March 28, 2024 – Zevra Therapeutics, Inc. (NasdaqGS:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/0001437749-24-009849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.